Navigation Links
OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
Date:9/6/2011

BOTHELL, Wash. and VANCOUVER, British Columbia, Sept. 6, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen (OGX-011/TV-1011), were published in the September issues of the journals Clinical Cancer Research and Cancer Research.

Custirsen inhibits the production of clusterin, a protein commonly over-produced in cancer cells and a cause of treatment resistance. Two Phase III studies evaluating custirsen in men with castrate-resistant prostate cancer (CRPC) are ongoing: the SYNERGY clinical trial - designed to evaluate an overall survival benefit for custirsen in combination with first-line docetaxel treatment, and the Prostate Cancer SATURN Trial - which will evaluate a durable pain palliation benefit in patients receiving second-line chemotherapy. Both studies are currently enrolling CRPC patients.

Phase II Data Published in Clinical Cancer Research

Data from a Phase II clinical study of custirsen in combination with docetaxel retreatment or mitoxantrone as second-line chemotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) was published in the September 1, 2011 issue of Clinical Cancer Research.

In the clinical study, custirsen combined with docetaxel retreatment resulted in overall survival of 15.8 months. When custirsen was combined with mitoxantrone, overall survival was 11.5 months. The Phase II study also evaluated pain responses in patients with mCRPC. Overall, the pain response was durable (greater than or equal to three months) in 88 percent of patients who had pain or were on opioids for pain at study entry.

"These are encouraging results because we observed durable pain responses in many patients who had di
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
2. OncoGenex Reports Third Quarter Financial Results
3. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
5. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
6. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
7. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
8. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
9. OncoGenex Reports Second Quarter Financial Results
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... and TEL AVIV, Israel , ... or the "Company") (NYSE MKT: NSPR), a leader in embolic ... the Company,s President and Chief Executive Officer, and ... participate in the Benchmark Company, LLC One-on-One Investor Conference on ... Wisconsin Ave., Milwaukee, WI. ...
(Date:5/24/2013)... DIEGO , May 24, 2013 ... company using proprietary taste science technologies to discover, develop, ... David Linemeyer , Ph.D., the Company,s Vice ... Vice President, Investor Relations & Corporate Communications, will present ... May 31, at 10:25 a.m. Eastern Time (7:25 a.m. ...
(Date:5/24/2013)... Dallas, Texas (PRWEB) May 24, 2013 ... web-based benchmarking survey on kinase profiling carried out ... data, details of the breakdown of the responses ... for the future (2015). It also highlights some ... Research survey groupings. Two bottom-up models were developed ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Many factors ... and uptake or efflux transporters at the blood-tissue barrier. ... related to unbound fractions in the tissue rather than ... these disposition challenges is required to guide lead optimization, ... identify any species-dependent variables that may impact the likely ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2
... 40.8% to $11.6 million ... Net Income increased 118.8% to $2.5 million, ... Medicine,Corporation (OTC Bulletin Board: CHME) ("China Medicine" or ... and over-the-counter,pharmaceuticals, traditional Chinese medicines ("TCM"), nutritional and,dietary-supplements, ...
... has announced the,appointment of David A. Mann to the ... of the Board,s audit committee., "Dave,s years of ... sector are an invaluable asset to Omeros,",stated Gregory Demopulos, ... addition to our Board, and I expect that he ...
... VIEW, California, August 13 BN,ImmunoTherapeutics, Inc. ... the,National Cancer Institute (NCI) in the United ... (CRADA) the NCI and BN,ImmunoTherapeutics will jointly ... cancer. Under the CRADA, BN ImmunoTherapeutics has,rights ...
Cached Biology Technology:China Medicine Announces Strong Second Quarter 2008 Results 2China Medicine Announces Strong Second Quarter 2008 Results 3China Medicine Announces Strong Second Quarter 2008 Results 4China Medicine Announces Strong Second Quarter 2008 Results 5China Medicine Announces Strong Second Quarter 2008 Results 6China Medicine Announces Strong Second Quarter 2008 Results 7China Medicine Announces Strong Second Quarter 2008 Results 8China Medicine Announces Strong Second Quarter 2008 Results 9China Medicine Announces Strong Second Quarter 2008 Results 10China Medicine Announces Strong Second Quarter 2008 Results 11Omeros Appoints David A. Mann to its Board of Directors 2BN ImmunoTherapeutics Announces Partnership With National Cancer Institute 2BN ImmunoTherapeutics Announces Partnership With National Cancer Institute 3
(Date:5/24/2013)... A conference of 500 leading water scientists from around ... major reforms, "in the short span of one or ... on Earth will be living under the handicap of ... resource for which there is no substitute. This handicap ... , The scientists bluntly pointed to chronic underlying problems ...
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) ... among grasses , Within the genome of each ... undergo little change in position and sequence over millions ... Some of these evolutionarily stable sequences, so-called conserved noncoding ... other genes or the condensation of chromosomes, but the ...
(Date:5/23/2013)... fruit, can be made both better-tasting and longer-lasting thanks ... "Working with GM tomatoes that are different to normal ... allows us to pinpoint exactly how to breed in ... Innes Centre. , The research could also lead to ... characteristics because even higher levels of the compounds can ...
Breaking Biology News(10 mins):A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2
... the parareptiles, a diverse group of bizarre-looking terrestrial vertebrates ... small, slender, agile and lizard-like creatures, while others attained ... and bony spikes on their skulls. The researchers ... by the end-Permian extinction than at any other point ...
... exposure to bisphenol A (BPA) during pregnancy is associated ... from families without parental BPA exposure in the workplace, ... study is published in the current online issue ... was a greater magnitude of decrease in birth weight ...
... -- Experts agree that obesity prevention should begin before children ... data, health care providers often have trouble advising parents about ... soon to be published in The Journal of Pediatrics ... be an effective way to help prevent obesity. Dr. ...
Cached Biology News:Reptile 'cousins' shed new light on end-Permian extinction 2Parental exposure to BPA during pregnancy associated with decreased birth weight in offspring 2Parental exposure to BPA during pregnancy associated with decreased birth weight in offspring 3Study suggests prolonged bottle feeding increases the risk of obesity 2